Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Silverman

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
International Journal of Radiation Oncology, Biology, Physics|November 2, 2010
A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancerWilliam C Chen, Janice Kim, Edward Kim, et al.
NPJ Breast Cancer|March 23, 2021
Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancerMaitri Kalra, Yan Tong, David R Jones, et al.
JAMA Health Forum|April 7, 2023
Group Home Staff Experiences With Work and Health in the COVID-19 Pandemic in MassachusettsKaren Donelan, Jessica Wolfe, Anna Wilson, et al.
JAMA|August 20, 2009
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized studyMatthew J Ellis, Feng Gao, Farrokh Dehdashti, et al.
Seminars in Oncology|February 19, 2005
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancerNicholas J Robert, Charles L Vogel, I Craig Henderson, et al.
Breast Cancer Research and Treatment|October 21, 2024
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108Vered Stearns, Anne ONeill, Bryan P Schneider, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkersJoseph Baar, Paula Silverman, Janice Lyons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerAnna Maria Storniolo, Mark D Pegram, Beth Overmoyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast CancerBora Lim, David A Potter, Mohamad A Salkeni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicinBeth Overmoyer, Pingfu Fu, Charles Hoppel, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
International Journal of Radiation Oncology, Biology, Physics|November 2, 2010
A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancerWilliam C Chen, Janice Kim, Edward Kim, et al.
NPJ Breast Cancer|March 23, 2021
Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancerMaitri Kalra, Yan Tong, David R Jones, et al.
JAMA Health Forum|April 7, 2023
Group Home Staff Experiences With Work and Health in the COVID-19 Pandemic in MassachusettsKaren Donelan, Jessica Wolfe, Anna Wilson, et al.
JAMA|August 20, 2009
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized studyMatthew J Ellis, Feng Gao, Farrokh Dehdashti, et al.
Seminars in Oncology|February 19, 2005
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancerNicholas J Robert, Charles L Vogel, I Craig Henderson, et al.
Breast Cancer Research and Treatment|October 21, 2024
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108Vered Stearns, Anne ONeill, Bryan P Schneider, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkersJoseph Baar, Paula Silverman, Janice Lyons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerAnna Maria Storniolo, Mark D Pegram, Beth Overmoyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast CancerBora Lim, David A Potter, Mohamad A Salkeni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicinBeth Overmoyer, Pingfu Fu, Charles Hoppel, et al.
Pageof 4